Through partnering with CABI, we can supply your organization with thousands of targeted strains or extracts from our collection. By screening our microorganisms for products, your scientists may be able to develop new sources of vitamins or discover drugs for improving health and combating diseases such MRSA and cancers.
Some of our current partnerships include:
British Antarctic Survey (BAS), whose collection has been taken into CABI’s care. We are also joining forces to explore these microorganisms for natural products.
PharmaLinks, which brings together the scientific and clinical expertise of the University of Glasgow and the University of Strathclyde. Pharmalinks are screening a targeted selection of our microorganisms and have a strong track record in providing industry with a wealth of new ideas for therapeutic targets, drug candidates and drug delivery.
Royal Botanic Gardens, Kew, who are chemically fingerprinting and screening a selection of our fungal endophyte extracts against insects and selected fungi and bacteria.
Royal Holloway, University of London, who possess specialised equipment and expertise to help with the biochemical characterisation and analysis of our microorganisms and extracts.
*New venture* Surrey Biotech is a new biotechnology venture formed by CABI and Royal Holloway, University of London. The aim is to identify new classes of antibiotics for clinical use against newly emerging and known pathogens that are resistant to existing antimicrobials. Funding is currently being sought.